Bio-Techne
Bio-Techne Quality Analysis
Bio-Techne (TECH) is an average quality business scoring 64/100. While the company generates positive returns, it lacks the exceptional attributes that characterize durable competitive advantages. Investors should demand a meaningful discount to fair value before investing.
Does Bio-Techne have a strong competitive moat?
Bio-Techne operates with a narrow competitive moat. While the business generates acceptable returns, it lacks the consistent margin superiority or return on capital that would indicate strong pricing power or durable competitive advantages. Competition could erode profitability over time.
Does Bio-Techne have pricing power in its industry?
Bio-Techne demonstrates moderate pricing power. The company maintains healthy margins and has been able to grow revenue without significant margin compression. Margins have remained relatively stable. This suggests reasonable, though not exceptional, ability to pass costs through to customers.
How predictable is Bio-Techne's business?
Bio-Techne is a highly predictable business with remarkably consistent financial performance. Revenue growth has been steady with low volatility, and the company has delivered positive free cash flow in 9 of the last 9 years. This consistency makes future earnings relatively easy to forecast with confidence.
Is Bio-Techne financially strong?
Bio-Techne has an exceptionally strong balance sheet with low leverage. The company could comfortably weather a severe economic downturn. This financial fortress provides strategic flexibility and reduces risk for long-term shareholders.
How effective is Bio-Techne's capital allocation strategy?
Bio-Techne has mixed capital allocation. Returns on capital are mediocre, suggesting some investments are not generating adequate returns. Management could be more disciplined in deploying shareholder capital.
Does Bio-Techne have high-quality management?
Bio-Techne's management shows mixed results. Operational efficiency could be improved, and capital deployment decisions have been inconsistent. The team needs to demonstrate clearer focus on shareholder value creation.
Is Bio-Techne a quality company?
Bio-Techne is an average quality company with a quality score of 64/100
Predicted probability of operating margin improvement over the next 12 months
- Predictability is the strongest dimension at 89/100.
- Capital allocation is the weakest area at 40/100 and needs attention.
- Average gross margin of 67.1% over 5 years.
- Positive free cash flow in 9 of the last 9 years.
What is the fair value of Bio-Techne stock?
Is Bio-Techne a good investment at $53?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.